Steven A Eschrich

List of Publications by Year in Descending Order

135 papers	8,820 citations	41 h-index	93 g-index
188 ext. papers	10,528 ext. citations	4.9 avg, IF	5.3 L-index

#	Paper	IF	Citations
135	Volume doubling time and radiomic features predict tumor behavior of screen-detected lung cancers.. *Cancer Biomarkers*, **2022**, 33, 489-501	3.8	0
134	Managing a Large-Scale Multiomics Project: A Team Science Case Study in Proteogenomics. *Methods in Molecular Biology*, **2021**, 2194, 187-221	1.4	
133	Tumor-immune ecosystem dynamics define an individual Radiation Immune Score to predict pan-cancer radiocurability. *Neoplasia*, **2021**, 23, 1110-1122	6.4	2
132	Metabolic Changes Are Associated with Melphalan Resistance in Multiple Myeloma. *Journal of Proteome Research*, **2021**, 20, 3134-3149	5.6	2
131	Hypoxia-Related Radiomics and Immunotherapy Response: A Multicohort Study of Non-Small Cell Lung Cancer. *JNCI Cancer Spectrum*, **2021**, 5, pkab048	4.6	3
130	Enabling Precision Medicine in Cancer Care Through a Molecular Data Warehouse: The Moffitt Experience. *JCO Clinical Cancer Informatics*, **2021**, 5, 561-569	5.2	1
129	Effects of long-term norepinephrine treatment on normal immortalized ovarian and fallopian tube cells. *Scientific Reports*, **2021**, 11, 14334	4.9	0
128	Personalizing Radiotherapy Prescription Dose Using Genomic Markers of Radiosensitivity and Normal Tissue Toxicity in NSCLC. *Journal of Thoracic Oncology*, **2021**, 16, 428-438	8.9	14
127	Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis. *Lancet Oncology, The*, **2021**, 22, 1221-1229	21.7	16
126	Genome-wide host methylation profiling of anal and cervical carcinoma. *PLoS ONE*, **2021**, 16, e0260857	3.7	1
125	Empirically-derived synthetic populations to mitigate small sample sizes. *Journal of Biomedical Informatics*, **2020**, 105, 103408	10.2	2
124	Peritumoral and intratumoral radiomic features predict survival outcomes among patients diagnosed in lung cancer screening. *Scientific Reports*, **2020**, 10, 10528	4.9	9
123	Metabolomics of primary cutaneous melanoma and matched adjacent extratumoral microenvironment. *PLoS ONE*, **2020**, 15, e0240849	3.7	4
122	Primary tumors from mucosal barrier organs drive unique eosinophil infiltration patterns and clinical associations. *OncoImmunology*, **2020**, 10, 1859732	7.2	4
121	Using the Radiosensitivity Index (RSI) to Predict Pelvic Failure in Endometrial Cancer Treated With Adjuvant Radiation Therapy. *International Journal of Radiation Oncology Biology Physics*, **2020**, 106, 496-502	4	12
120	LC-HRMS of derivatized urinary estrogens and estrogen metabolites in postmenopausal women. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2020**, 1154, 122288	3.2	1
119	GMSimpute: a generalized two-step Lasso approach to impute missing values in label-free mass spectrum analysis. *Bioinformatics*, **2020**, 36, 257-263	7.2	9

118	EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors. *Cancer Genomics and Proteomics*, **2019**, 16, 309-318	3.3	2
117	Proteometabolomics of Melphalan Resistance in Multiple Myeloma. *Methods in Molecular Biology*, **2019**, 1996, 273-296	1.4	2
116	An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines. *Cancer Research*, **2019**, 79, 1263-1273	10.1	24
115	Inhibition of the FAD containing ER oxidoreductin 1 (Ero1) protein by EN-460 as a strategy for treatment of multiple myeloma. *Bioorganic and Medicinal Chemistry*, **2019**, 27, 1479-1488	3.4	12
114	Proteogenomic landscape of squamous cell lung cancer. *Nature Communications*, **2019**, 10, 3578	17.4	34
113	Utilizing the genomically adjusted radiation dose (GARD) to personalize adjuvant radiotherapy in triple negative breast cancer management. *EBioMedicine*, **2019**, 47, 163-169	8.8	16
112	Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual Targets. *Cell Chemical Biology*, **2019**, 26, 1240-1252.e11	8.2	8
111	Transforming growth factor induced epithelial-to-mesenchymal signature predicts metastasis-free survival in non-small cell lung cancer. *Oncotarget*, **2019**, 10, 810-824	3.3	14
110	Integrated Multi-Level Omics to Characterize Bortezomib Resistance in Multiple Myeloma. *Blood*, **2019**, 134, 5534-5534	2.2	
109	Proteometabolomics of Melphalan Resistance in Multiple Myeloma. *Blood*, **2018**, 132, 5619-5619	2.2	
108	Expression of CAS/CSE1L, the Cellular Apoptosis Susceptibility Protein, Correlates With Neoplastic Progression in Barrett's Esophagus. *Applied Immunohistochemistry and Molecular Morphology*, **2018**, 26, 552-556	1.9	6
107	Radiosensitivity of Lung Metastases by Primary Histology and Implications for Stereotactic Body Radiation Therapy Using the Genomically Adjusted Radiation Dose. *Journal of Thoracic Oncology*, **2018**, 13, 1121-1127	8.9	33
106	Relative protein quantification and accessible biology in lung tumor proteomes from four LC-MS/MS discovery platforms. *Proteomics*, **2017**, 17, 1600300	4.8	13
105	Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2017**, 15, 473-482	7.3	14
104	The radiosensitivity of brain metastases based upon primary histology utilizing a multigene index of tumor radiosensitivity. *Neuro-Oncology*, **2017**, 19, 1145-1146	1	13
103	A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. *Lancet Oncology, The*, **2017**, 18, 202-211	21.7	227
102	Characteristics and Validation Techniques for PCA-Based Gene-Expression Signatures. *International Journal of Genomics*, **2017**, 2017, 2354564	2.5	15
101	Evaluating somatic tumor mutation detection without matched normal samples. *Human Genomics*, **2017**, 11, 22	6.8	28

100	Integrating Biological Covariates into Gene Expression-Based Predictors of Radiation Sensitivity. *International Journal of Genomics*, **2017**, 2017, 6576840	2.5	5
99	Tumour radiosensitivity is associated with immune activation in solid tumours. *European Journal of Cancer*, **2017**, 84, 304-314	7.5	27
98	Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility. *JMIR Research Protocols*, **2017**, 6, e45	2	6
97	Methylomic classifiers of anal cancer outcomes: An NRG Oncology / RTOG 98-11 tissue study.. *Journal of Clinical Oncology*, **2017**, 35, 588-588	2.2	
96	Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. *Oncogene*, **2016**, 35, 3209-16	9.2	160
95	Knockdown of CSE1L Gene in Colorectal Cancer Reduces Tumorigenesis inⓋitro. *American Journal of Pathology*, **2016**, 186, 2761-8	5.8	19
94	Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer. *Molecular Cancer Research*, **2016**, 14, 1019-1029	6.6	42
93	Differences in Patient Outcomes of Prevalence, Interval, and Screen-Detected Lung Cancers in the CT Arm of the National Lung Screening Trial. *PLoS ONE*, **2016**, 11, e0159880	3.7	37
92	Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma. *Oncotarget*, **2016**, 7, 82254-82265	3.3	6
91	Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes following SBRT.. *Journal of Clinical Oncology*, **2016**, 34, 239-239	2.2	0
90	Genomically adjusted radiation dose to predict for survival with adjuvant radiation in resectable pancreatic cancer.. *Journal of Clinical Oncology*, **2016**, 34, 240-240	2.2	
89	Activity-Based Proteomics Reveals Heterogeneous Kinome and ATP-Binding Proteome Responses to MEK Inhibition in KRAS Mutant Lung Cancer. *Proteomes*, **2016**, 4, 16	4.6	5
88	ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. *PLoS ONE*, **2016**, 11, e0147344	3.7	67
87	Association Between Computed Tomographic Features and Kirsten Rat Sarcoma Viral Oncogene Mutations in Patients With Stage I Lung Adenocarcinoma and Their Prognostic Value. *Clinical Lung Cancer*, **2016**, 17, 271-8	4.9	14
86	Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy. *International Journal of Radiation Oncology Biology Physics*, **2016**, 95, 1399-1404	4	93
85	APOSTL: An Interactive Galaxy Pipeline for Reproducible Analysis of Affinity Proteomics Data. *Journal of Proteome Research*, **2016**, 15, 4747-4754	5.6	14
84	Differences Between Colon Cancer Primaries and Metastases Using a Molecular Assay for Tumor Radiation Sensitivity Suggest Implications for Potential Oligometastatic SBRT Patient Selection. *International Journal of Radiation Oncology Biology Physics*, **2015**, 92, 837-42	4	62
83	Semiquantitative Computed Tomography Characteristics for Lung Adenocarcinoma and Their Association With Lung Cancer Survival. *Clinical Lung Cancer*, **2015**, 16, e141-63	4.9	36

82	Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer. *Radiotherapy and Oncology*, **2015**, 117, 159-64	5.3	48
81	Integration of a Radiosensitivity Molecular Signature Into the Assessment of Local Recurrence Risk in Breast Cancer. *International Journal of Radiation Oncology Biology Physics*, **2015**, 93, 631-8	4	77
80	Tolerance associated gene expression following allogeneic hematopoietic cell transplantation. *PLoS ONE*, **2015**, 10, e0117001	3.7	8
79	Quantitative computed tomographic descriptors associate tumor shape complexity and intratumor heterogeneity with prognosis in lung adenocarcinoma. *PLoS ONE*, **2015**, 10, e0118261	3.7	167
78	Differences between colon cancer primaries and metastases utilizing a molecular assay for tumor radiosensitivity and implications for potential oligometastatic SBRT patient selection.. *Journal of Clinical Oncology*, **2015**, 33, 569-569	2.2	1
77	A Pilot Proteogenomic Study with Data Integration Identifies MCT1 and GLUT1 as Prognostic Markers in Lung Adenocarcinoma. *PLoS ONE*, **2015**, 10, e0142162	3.7	22
76	The radiosensitivity index predicts for overall survival in glioblastoma. *Oncotarget*, **2015**, 6, 34414-22	3.3	72
75	Radiosensitivity index prognostic for survival with adjuvant radiation in resectable pancreatic cancer.. *Journal of Clinical Oncology*, **2015**, 33, 398-398	2.2	
74	Test-retest reproducibility analysis of lung CT image features. *Journal of Digital Imaging*, **2014**, 27, 805-23	3.3	163
73	A Molecular Signature of Radiosensitivity (RSI) is an RT-specific Biomarker in Prostate Cancer. *International Journal of Radiation Oncology Biology Physics*, **2014**, 90, S157	4	10
72	Radiosensitivity Index Shows Promise for Predicting Outcomes With Adjuvant Radiation in Resected Pancreatic Cancer Patients. *International Journal of Radiation Oncology Biology Physics*, **2014**, 90, S174	4	5
71	Expanding epigenomics to archived FFPE tissues: an evaluation of DNA repair methodologies. *Cancer Epidemiology Biomarkers and Prevention*, **2014**, 23, 2622-31	4	17
70	Quantification of peptides from immunoglobulin constant and variable regions by LC-MRM MS for assessment of multiple myeloma patients. *Proteomics - Clinical Applications*, **2014**, 8, 783-95	3.1	22
69	Epigenomic characterization of locally advanced anal cancer: a radiation therapy oncology group 98-11 specimen study. *Diseases of the Colon and Rectum*, **2014**, 57, 941-57	3.1	9
68	Computational methods and opportunities for phosphorylation network medicine. *Translational Cancer Research*, **2014**, 3, 266-278	0.3	6
67	Iterative rank-order normalization of gene expression microarray data. *BMC Bioinformatics*, **2013**, 14, 153	3.6	77
66	Development and application of a novel metric to assess effectiveness of biomedical data. *BMJ Open*, **2013**, 3, e003220	3	1
65	Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms. *Molecular Systems Biology*, **2013**, 9, 705	12.2	37

64	Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 12414-9	11.5	72
63	Personalized medicine for radiation therapy. *Personalized Medicine*, **2013**, 10, 107-110	2.2	
62	12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?. *Scientific Reports*, **2012**, 2, 765	4.9	231
61	Radiomics: the process and the challenges. *Magnetic Resonance Imaging*, **2012**, 30, 1234-48	3.3	1156
60	Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of ß-catenin. *Gastroenterology*, **2012**, 142, 562-571.e2	13.3	132
59	Informatics methods to enable sharing of quantitative imaging research data. *Magnetic Resonance Imaging*, **2012**, 30, 1249-56	3.3	13
58	Validation of a radiosensitivity molecular signature in breast cancer. *Clinical Cancer Research*, **2012**, 18, 5134-43	12.9	136
57	The metabolomic signature of malignant glioma reflects accelerated anabolic metabolism. *Cancer Research*, **2012**, 72, 5878-88	10.1	113
56	ITERATIVE FEATURE PERTURBATION AS A GENE SELECTOR FOR MICROARRAY DATA. *International Journal of Pattern Recognition and Artificial Intelligence*, **2012**, 26, 1260003	1.1	19
55	Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. *Cancer Research*, **2012**, 72, 2501-11	10.1	88
54	DNA methylation profiling across the spectrum of HPV-associated anal squamous neoplasia. *PLoS ONE*, **2012**, 7, e50533	3.7	18
53	Abstract IA2: Network models in oncogene-addicted lung cancer. *Clinical Cancer Research*, **2012**, 18, IA2-IA2	12.9	
52	Claudin-1 up-regulates the repressor ZEB-1 to inhibit E-cadherin expression in colon cancer cells. *Gastroenterology*, **2011**, 141, 2140-53	13.3	117
51	Necdin, a negative growth regulator, is a novel STAT3 target gene down-regulated in human cancer. *PLoS ONE*, **2011**, 6, e24923	3.7	14
50	Claudin-2 expression increases tumorigenicity of colon cancer cells: role of epidermal growth factor receptor activation. *Oncogene*, **2011**, 30, 3234-47	9.2	101
49	Evolutionary computation with noise perturbation and cluster analysis to discover biomarker sets. *Procedia Computer Science*, **2011**, 6, 153-158	1.6	2
48	Partial Least Squares (PLS) Applied to Medical Bioinformatics. *Procedia Computer Science*, **2011**, 6, 273-278	1.8	16
47	A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer. *Proteomics - Clinical Applications*, **2011**, 5, 383-96	3.1	43

46	Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity. *Journal of Proteome Research*, **2011**, 10, 305-19	5.6	52
45	BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. *Clinical Cancer Research*, **2011**, 17, 6356-66	12.9	67
44	Monitoring a nuclear factor-**B** signature of drug resistance in multiple myeloma. *Molecular and Cellular Proteomics*, **2011**, 10, M110.005520	7.6	27
43	BVES regulates EMT in human corneal and colon cancer cells and is silenced via promoter methylation in human colorectal carcinoma. *Journal of Clinical Investigation*, **2011**, 121, 4056-69	15.9	52
42	HDAC inhibitors regulate claudin-1 expression in colon cancer cells through modulation of mRNA stability. *Oncogene*, **2010**, 29, 305-12	9.2	75
41	A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. *Nature Chemical Biology*, **2010**, 6, 291-9	11.7	221
40	Characterizing tyrosine phosphorylation signaling in lung cancer using SH2 profiling. *PLoS ONE*, **2010**, 5, e13470	3.7	29
39	Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. *Gastroenterology*, **2010**, 138, 958-68	13.3	454
38	Biomarkers to discern transplantation tolerance after allogeneic hematopoietic cell transplantation. *Biology of Blood and Marrow Transplantation*, **2010**, 16, 729-38	4.7	6
37	Quantification of beta-catenin signaling components in colon cancer cell lines, tissue sections, and microdissected tumor cells using reaction monitoring mass spectrometry. *Journal of Proteome Research*, **2010**, 9, 4215-27	5.6	44
36	Discovery and Validation of a Novel Set of Putative Progression Markers in Well-Differentiated Primary Pancreatic Endocrine Carcinomas. *Pancreas*, **2010**, 39, 277-278	2.6	1
35	Gene expression profiling of colorectal mucinous adenocarcinomas. *Diseases of the Colon and Rectum*, **2010**, 53, 936-43	3.1	32
34	Methods for investigation of targeted kinase inhibitor therapy using chemical proteomics and phosphorylation profiling. *Biochemical Pharmacology*, **2010**, 80, 739-47	6	15
33	Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer. *Clinical Cancer Research*, **2009**, 15, 7642-7651	12.9	320
32	A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. *International Journal of Radiation Oncology Biology Physics*, **2009**, 75, 489-96	4	203
31	Systems biology modeling of the radiation sensitivity network: a biomarker discovery platform. *International Journal of Radiation Oncology Biology Physics*, **2009**, 75, 497-505	4	172
30	Gene expression profiles as predictors of poor outcomes in stage II colorectal cancer: A systematic review and meta-analysis. *Clinical Colorectal Cancer*, **2009**, 8, 207-14	3.8	22
29	Removal of hybridization and scanning noise from microarrays. *IEEE Transactions on Nanobioscience* , **2009**, 8, 210-8	3.4	5

28	Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. *Nature Medicine*, **2008**, 14, 822-7	50.5	835
27	A predictive risk probability approach for microarray data with survival as an endpoint. *Journal of Biopharmaceutical Statistics*, **2008**, 18, 841-52	1.3	1
26	Toward a measure of classification complexity in gene expression signatures. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference*, **2008**, 2008, 5704-7	0.9	3
25	IPEP: an in silico tool to examine proteolytic peptides for mass spectrometry. *Bioinformatics*, **2008**, 24, 2801-2	7.2	10
24	Towards a framework for analysis of biophotonic images of mouse models of cancer. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference*, **2008**, 2008, 3079-82	0.9	1
23	Feature selection for microarray data by AUC analysis. *Conference Proceedings IEEE International Conference on Systems, Man, and Cybernetics*, **2008**,	2	3
22	Tissue-specific RMA models to incrementally normalize Affymetrix GeneChip data. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference*, **2008**, 2008, 2419-22	0.9	3
21	The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. *BMC Medical Genomics*, **2008**, 1, 13	3.7	367
20	Down-regulation of Bax-interacting factor-1 in colorectal adenocarcinoma. *Cancer*, **2008**, 113, 2665-70	6.4	71
19	Insig2 is associated with colon tumorigenesis and inhibits Bax-mediated apoptosis. *International Journal of Cancer*, **2008**, 123, 273-282	7.5	14
18	Green tea catechins suppress the DNA synthesis marker MCM7 in the TRAMP model of prostate cancer. *Molecular Oncology*, **2007**, 1, 196-204	7.9	20
17	An exact test for detecting inconsistency in readers interpretation over time in screening mammograms. *Biometrical Journal*, **2007**, 49, 672-81	1.5	1
16	Elucidation of a protein signature discriminating six common types of adenocarcinoma. *International Journal of Cancer*, **2007**, 120, 769-75	7.5	30
15	Libaffy: software for processing Affymetrix GeneChip data. *Bioinformatics*, **2007**, 23, 1562-4	7.2	11
14	Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. *Genome Biology*, **2007**, 8, R131	18.3	270
13	Multivariate Feature Selection using Random Subspace Classifiers for Gene Expression Data **2007**,		2
12	Noise-Based Feature Perturbation as a Selection Method for Microarray Data **2007**, 237-247		6
11	Slicing: A Distributed Learning Approach **2006**, 55-97		

List of Publications

10	Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. *Clinical Cancer Research*, **2006**, 12, 11-9	12.9	422
9	Molecular staging for survival prediction of colorectal cancer patients. *Journal of Clinical Oncology*, **2005**, 23, 3526-35	2.2	285
8	Prediction of radiation sensitivity using a gene expression classifier. *Cancer Research*, **2005**, 65, 7169-76	10.1	155
7	A Comparison of Ensemble Creation Techniques. *Lecture Notes in Computer Science*, **2004**, 223-232	0.9	21
6	DNA microarrays and data analysis: an overview. *Surgery*, **2004**, 136, 500-3	3.6	13
5	Multi-platform, multi-site, microarray-based human tumor classification. *American Journal of Pathology*, **2004**, 164, 9-16	5.8	178
4	Is Error-Based Pruning Redeemable?. *International Journal on Artificial Intelligence Tools*, **2003**, 12, 249-264	0.9	4
3	Fast accurate fuzzy clustering through data reduction. *IEEE Transactions on Fuzzy Systems*, **2003**, 11, 262-270	2.7	136
2	Harnessing tumor immune ecosystem dynamics to personalize radiotherapy		1
1	Hypoxia-related radiomics predict immunotherapy response: A multi-cohort study of NSCLC		3